NCT07387211

Brief Summary

The aim of the study is to find the proportion of people in the population of the Olomouc Region with the presence of IgG (or IgM) antibodies against the S and N antigens of the SARS-CoV-2 virus, therefore people who have already encountered the SARS-CoV-2 virus with manifest antibody formation, or people who have undergone vaccination against COVID-19.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,484

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 18, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 13, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 13, 2022

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

January 28, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 4, 2026

Completed
Last Updated

February 4, 2026

Status Verified

January 1, 2026

Enrollment Period

9 months

First QC Date

January 28, 2026

Last Update Submit

January 28, 2026

Conditions

SARS-CoV-2SARS-CoV-2 (COVID-19) Infection

Keywords

SARS-CoV-2

Outcome Measures

Primary Outcomes (1)

  • The proportion of people in the population of the Olomouc Region with the presence of antibodies against the SARS-CoV-2 virus

    The proportion of people in the population of the Olomouc Region with the presence of IgG (or IgM) antibodies against the S and N antigens of the SARS-CoV-2 virus, therefore people who have already encountered the SARS-CoV-2 virus with manifest antibody formation, or people who have undergone vaccination against COVID-19.

    12 months

Secondary Outcomes (4)

  • Quantification of the level/presence of cellular immunity

    12 months

  • Verification of the presence of the SARS-CoV-2 virus

    12 months

  • Proportion of people with an asymptomatic course of SARS-CoV-2 disease

    12 months

  • Quantification of the presence of antibodies and the presence of cellular immunity

    12 months

Study Arms (1)

Participants of the SARS-CoV-2-CZ-Preval study from the Olomouc region

OTHER

Population of persons involved in the SARS-CoV-2-CZ-Preval study in 2020 in the Olomouc region

Procedure: Blood samplingProcedure: Gargle samplingOther: Questionnaire completionDiagnostic Test: Body temperature measurement

Interventions

Blood samplingPROCEDURE

Venous blood sampling three times on three visits of the study.

Participants of the SARS-CoV-2-CZ-Preval study from the Olomouc region
Gargle samplingPROCEDURE

Gargle sampling using GARGTEST sampling kit on three visits of the study and also gargle self-sampling using GARGTEST sampling kit at 14-day intervals between the study visits.

Participants of the SARS-CoV-2-CZ-Preval study from the Olomouc region
Questionnaire completionOTHER

Patient will complete questionnaire on each visit on SARS-CoV-2 infections and vaccinations

Participants of the SARS-CoV-2-CZ-Preval study from the Olomouc region
Body temperature measurementDIAGNOSTIC_TEST

Body temperature will be measured by healthcare professional at each visit to exclude patients with acute infection.

Participants of the SARS-CoV-2-CZ-Preval study from the Olomouc region

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participation in the SARS-CoV-2-CZ-PREVAL study and venous blood examined as part of this study
  • Signed study informed consent and consent to the processing of personal data
  • Adults (age 18 and over)
  • Willingness to complete the questionnaire

You may not qualify if:

  • Participant with acute health problems

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Olomouc

Olomouc, 77900, Czechia

Location

MeSH Terms

Conditions

COVID-19Infections

Interventions

Blood Specimen CollectionBody Temperature

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesVital SignsPhysical ExaminationPhysiological Phenomena

Study Officials

  • Marian Hajduch, MD, PhD

    Palacky University Olomouc

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 28, 2026

First Posted

February 4, 2026

Study Start

January 18, 2022

Primary Completion

October 13, 2022

Study Completion

October 13, 2022

Last Updated

February 4, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

CZ(1)